219 related articles for article (PubMed ID: 8764341)
1. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat.
Bickel U; Schumacher OP; Kang YS; Voigt K
J Pharmacol Exp Ther; 1996 Jul; 278(1):107-13. PubMed ID: 8764341
[TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine.
Abbruscato TJ; Thomas SA; Hruby VJ; Davis TP
J Pharmacol Exp Ther; 1997 Jan; 280(1):402-9. PubMed ID: 8996221
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
4. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
[TBL] [Abstract][Full Text] [Related]
5. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.
Poduslo JF; Curran GL; Sanyal B; Selkoe DJ
Neurobiol Dis; 1999 Jun; 6(3):190-9. PubMed ID: 10408808
[TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine.
Wu D; Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1997 Jun; 25(6):768-71. PubMed ID: 9193881
[TBL] [Abstract][Full Text] [Related]
7. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding.
Liu X; Smith BJ; Chen C; Callegari E; Becker SL; Chen X; Cianfrogna J; Doran AC; Doran SD; Gibbs JP; Hosea N; Liu J; Nelson FR; Szewc MA; Van Deusen J
J Pharmacol Exp Ther; 2005 Jun; 313(3):1254-62. PubMed ID: 15743928
[TBL] [Abstract][Full Text] [Related]
8. Modulation of metabolic effects of morphine-6-glucuronide by morphine-3-glucuronide.
Hashiguchi Y; Molina PE; Abumrad NN
Brain Res Bull; 1995; 38(4):325-9. PubMed ID: 8535854
[TBL] [Abstract][Full Text] [Related]
9. Transport is not rate-limiting in morphine glucuronidation in the single-pass perfused rat liver preparation.
Doherty MM; Poon K; Tsang C; Pang KS
J Pharmacol Exp Ther; 2006 May; 317(2):890-900. PubMed ID: 16464965
[TBL] [Abstract][Full Text] [Related]
10. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier.
Poduslo JF; Curran GL; Haggard JJ; Biere AL; Selkoe DJ
Neurobiol Dis; 1997; 4(1):27-34. PubMed ID: 9258909
[TBL] [Abstract][Full Text] [Related]
11. Diffusion of morphine-6-beta-D-glucuronide into the neonatal guinea pig brain during drug-induced respiratory depression.
Murphey LJ; Olsen GD
J Pharmacol Exp Ther; 1994 Oct; 271(1):118-24. PubMed ID: 7965704
[TBL] [Abstract][Full Text] [Related]
12. Brain to blood efflux transport of adenosine: blood-brain barrier studies in the rat.
Isakovic AJ; Abbott NJ; Redzic ZB
J Neurochem; 2004 Jul; 90(2):272-86. PubMed ID: 15228584
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of papaverine-mediated blood-brain barrier disruption in rats.
Bhattacharjee AK; Kondoh T; Nagashima T; Ikeda M; Ehara K; Tamaki N
Biochem Biophys Res Commun; 2001 Nov; 289(2):548-52. PubMed ID: 11716508
[TBL] [Abstract][Full Text] [Related]
14. Systemic coadministration of chloramphenicol with intravenous but not intracerebroventricular morphine markedly increases morphine antinociception and delays development of antinociceptive tolerance in rats.
Smith MT; Nielsen CK; Lim-Fraser MY; Wright AW; Lau M
Drug Metab Dispos; 2000 Feb; 28(2):236-44. PubMed ID: 10640523
[TBL] [Abstract][Full Text] [Related]
15. Sex-dependent influences of morphine and its metabolites on pain sensitivity in the rat.
Doyle HH; Murphy AZ
Physiol Behav; 2018 Apr; 187():32-41. PubMed ID: 29199028
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the disposition of hepatically-generated morphine-3-glucuronide and morphine-6-glucuronide in isolated perfused liver from the guinea pig.
Milne RW; Jensen RH; Larsen C; Evans AM; Nation RL
Pharm Res; 1997 Aug; 14(8):1014-8. PubMed ID: 9279882
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro evidence for nonrestricted transport of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein tetraacetoxymethyl ester at the blood-brain barrier.
Hirohashi T; Terasaki T; Shigetoshi M; Sugiyama Y
J Pharmacol Exp Ther; 1997 Feb; 280(2):813-9. PubMed ID: 9023295
[TBL] [Abstract][Full Text] [Related]
18. Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability.
Stain-Texier F; Boschi G; Sandouk P; Scherrmann JM
Br J Pharmacol; 1999 Oct; 128(4):917-24. PubMed ID: 10556926
[TBL] [Abstract][Full Text] [Related]
19. A narrow time-window for access to the brain by exogenous protein after immunological targeting of a blood-brain barrier antigen.
N Ghabriel M; J Lu J; Tadros R; Hermanis G
J Comp Pathol; 2004 Jul; 131(1):52-60. PubMed ID: 15144799
[TBL] [Abstract][Full Text] [Related]
20. Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport.
Xie R; Bouw MR; Hammarlund-Udenaes M
Br J Pharmacol; 2000 Dec; 131(8):1784-92. PubMed ID: 11139459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
